Foldrx Report issue

Contributed to NME For profit Phase 3
Founded: Cambridge MA United States (2003)
Status: Acquired by Pfizer (2010)

Organization Overview

First Clinical Trial
2007
NCT00409175
First Marketed Drug
2019
tafamidis (Vyndaqel)
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

FoldRx Pharmaceuticals, Inc. | FOLDRX PHARMS

Active Ingredients

Marketed Drugs (1)

tafamidis (Vyndaqel) (2019)

Drugs in Phase 3 Trials (1)

tafamidis (Vyndaqel) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyloid Neuropathies (Phase 3)

Amyloid Neuropathies, Familial (Phase 3)

Amyloidosis (Phase 3)

Cardiomyopathies (Phase 2)

Polyneuropathies (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1